Marco Balducelli

Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica.

A Maresta, Marco Balducelli, Luca Cantini et al. · Circulation · 1994 · 151 citations · Full text

Medicine, Cardiology, Pharmacology +17

Single or multivessel percutaneous coronary intervention in ST‐elevation myocardial infarction patients

Elisabetta Varani, Marco Balducelli, Matteo Aquilina et al. · Catheterization and Cardiovascular Interventions · 2008 · 107 citations · Full text

Medicine, Cardiology, Surgery +10

Two-Year Clinical Outcomes With Drug-Eluting Stents for Diabetic Patients With De Novo Coronary Lesions

Paolo Ortolani, Marco Balducelli, Paolo Marzaroli et al. · Circulation · 2008 · 69 citations

Medicine, Cardiology, Internal Medicine +13

Off-Hour Primary Percutaneous Coronary Angioplasty Does Not Affect Outcome of Patients With ST-Segment Elevation Acute Myocardial Infarction Treated Within a Regional Network for Reperfusion

Gianni Casella, Filippo Ottani, Paolo Ortolani et al. · JACC: Cardiovascular Interventions · 2011 · 59 citations

Medicine, Cardiology, Surgery +12

Comparison of Effectiveness and Safety of Sirolimus-Eluting Stents Versus Bare-Metal Stents in Patients With Diabetes Mellitus (from the Italian Multicenter Randomized DESSERT Study)

A Maresta, Elisabetta Varani, Marco Balducelli et al. · The American Journal of Cardiology · 2008 · 50 citations

Medicine, Cardiology, Internal Medicine +12